Cited 26 times in
Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍사민 | - |
dc.contributor.author | 김찬윤 | - |
dc.contributor.author | 성공제 | - |
dc.date.accessioned | 2014-12-21T16:52:03Z | - |
dc.date.available | 2014-12-21T16:52:03Z | - |
dc.date.issued | 2007 | - |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/96501 | - |
dc.description.abstract | PURPOSE: The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2% versus brimonidine Purite 0.15% in Asians with ocular hypertension. METHODS: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. RESULTS: The baseline intraocular pressure (IOP) was 24.4 +/- 2.45 mmHg for brimonidine 0.2% and 24.39 +/- 2.56 mmHg for brimonidine Purite 0.15% (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% therapy were 20.10 +/- 2.01 mmHg and 21.00 +/- 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% treatment were 18.10 +/- 1.73 mmHg and 18.20 +/- 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2% was found to cause more allergic conjunctivitis than brimonidine Purite 0.15% (P < 0.001). CONCLUSIONS: Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 481~486 | - |
dc.relation.isPartOf | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Topical | - |
dc.subject.MESH | Adrenergic alpha-Agonists/administration & dosage | - |
dc.subject.MESH | Adrenergic alpha-Agonists/adverse effects | - |
dc.subject.MESH | Adrenergic alpha-Agonists/therapeutic use* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antihypertensive Agents/administration & dosage | - |
dc.subject.MESH | Antihypertensive Agents/adverse effects | - |
dc.subject.MESH | Antihypertensive Agents/therapeutic use* | - |
dc.subject.MESH | Asia | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Brimonidine Tartrate | - |
dc.subject.MESH | Conjunctivitis, Allergic/chemically induced | - |
dc.subject.MESH | Cross-Over Studies | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intraocular Pressure/drug effects | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Ocular Hypertension/drug therapy* | - |
dc.subject.MESH | Ophthalmic Solutions | - |
dc.subject.MESH | Pigment Epithelium of Eye/metabolism | - |
dc.subject.MESH | Preservatives, Pharmaceutical* | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Quinoxalines/administration & dosage | - |
dc.subject.MESH | Quinoxalines/adverse effects | - |
dc.subject.MESH | Quinoxalines/therapeutic use* | - |
dc.subject.MESH | Single-Blind Method | - |
dc.subject.MESH | Therapeutic Equivalency | - |
dc.title | Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | Chan Yun Kim | - |
dc.contributor.googleauthor | Samin Hong | - |
dc.contributor.googleauthor | Gong Je Seong | - |
dc.identifier.doi | 10.1089/jop.2007.0042 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A04395 | - |
dc.contributor.localId | A01035 | - |
dc.contributor.localId | A01946 | - |
dc.relation.journalcode | J01654 | - |
dc.identifier.eissn | 1557-7732 | - |
dc.identifier.pmid | 17900227 | - |
dc.identifier.url | http://online.liebertpub.com/doi/abs/10.1089/jop.2007.0042 | - |
dc.contributor.alternativeName | Hong, Sa Min | - |
dc.contributor.alternativeName | Kim, Chan Yun | - |
dc.contributor.alternativeName | Seong, Gong Je | - |
dc.contributor.affiliatedAuthor | Hong, Sa Min | - |
dc.contributor.affiliatedAuthor | Kim, Chan Yun | - |
dc.contributor.affiliatedAuthor | Seong, Gong Je | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 23 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 481 | - |
dc.citation.endPage | 486 | - |
dc.identifier.bibliographicCitation | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, Vol.23(5) : 481-486, 2007 | - |
dc.identifier.rimsid | 36121 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.